CN101657210A - 粘膜疾病引起的组织退化、损伤或损害的治疗或预防方法 - Google Patents

粘膜疾病引起的组织退化、损伤或损害的治疗或预防方法 Download PDF

Info

Publication number
CN101657210A
CN101657210A CN200880011935A CN200880011935A CN101657210A CN 101657210 A CN101657210 A CN 101657210A CN 200880011935 A CN200880011935 A CN 200880011935A CN 200880011935 A CN200880011935 A CN 200880011935A CN 101657210 A CN101657210 A CN 101657210A
Authority
CN
China
Prior art keywords
day
mucositis
scv
days
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880011935A
Other languages
English (en)
Chinese (zh)
Inventor
伊斯雷尔·里奥斯
辛西娅·塔特希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of CN101657210A publication Critical patent/CN101657210A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880011935A 2007-02-13 2008-02-11 粘膜疾病引起的组织退化、损伤或损害的治疗或预防方法 Pending CN101657210A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90097707P 2007-02-13 2007-02-13
US60/900,977 2007-02-13

Publications (1)

Publication Number Publication Date
CN101657210A true CN101657210A (zh) 2010-02-24

Family

ID=39690681

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880011935A Pending CN101657210A (zh) 2007-02-13 2008-02-11 粘膜疾病引起的组织退化、损伤或损害的治疗或预防方法

Country Status (14)

Country Link
US (2) US7906486B2 (cg-RX-API-DMAC7.html)
EP (1) EP2120986A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010518160A (cg-RX-API-DMAC7.html)
KR (1) KR20090119897A (cg-RX-API-DMAC7.html)
CN (1) CN101657210A (cg-RX-API-DMAC7.html)
AR (1) AR065338A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008216799A1 (cg-RX-API-DMAC7.html)
CA (1) CA2677749A1 (cg-RX-API-DMAC7.html)
IL (1) IL200364A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009008641A (cg-RX-API-DMAC7.html)
NZ (1) NZ579570A (cg-RX-API-DMAC7.html)
TW (1) TW200845958A (cg-RX-API-DMAC7.html)
UA (1) UA96980C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008100458A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109528202A (zh) * 2018-11-14 2019-03-29 北京大学第医院 一种头颈部放疗诊疗系统

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008641A (es) * 2007-02-13 2009-09-14 Sciclone Pharmaceuticals Inc Composiciones para el tratamiento o prevencion del deterioro, lesion o daño a tejido debido a enfermedad de las mucosas.
RU2436587C1 (ru) * 2010-10-21 2011-12-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") N-изовалероил-l-глутамил-l-триптофан как средство, препятствующее язвообразованию в желудке и двенадцатиперстной кишке

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125626A (en) 1977-01-17 1978-11-14 Mt. Sinai School Of Medicine Of The City University Of New York Synthesis and use of L-γ-glutamyl-DOPA
US4568489A (en) 1984-06-29 1986-02-04 E. R. Squibb & Sons, Inc. N-Acyl-γ-glutamyl imino and amino acids and esters
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4758551A (en) 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
US4968672A (en) 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4895835A (en) 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5206220A (en) 1990-04-23 1993-04-27 Research Corporation Technologies, Inc. Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition
WO1992017191A1 (en) 1991-04-01 1992-10-15 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
DE69230500D1 (de) 1991-10-28 2000-02-03 Cytran Ltd Pharmazeutische Dipeptid Zusammensetzungen und Verwendungsmethoden.
AU6359594A (en) 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
GB9320820D0 (en) 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
RU2107692C1 (ru) 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
US5888980A (en) 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
WO1997019691A1 (en) 1995-11-28 1997-06-05 Wei, Edward, T. Gamma-l-glutamyl containing immunomodulator compounds and methods therewith
US5744452A (en) 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
RU2120298C1 (ru) 1995-11-28 1998-10-20 Товарищество с ограниченной ответственностью "Верта" Иммуностимулятор и препарат на его основе
US5916878A (en) 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US6060452A (en) 1996-03-13 2000-05-09 Cytran, Inc. Analogs of L-Glu-L-Trp having pharmacological activity
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
RU2229892C2 (ru) 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких
US7173013B2 (en) 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
US20050256042A1 (en) * 2003-05-09 2005-11-17 Jeffers Michael E Methods of preventing and treating alimentary mucositis
MXPA06013050A (es) * 2004-05-14 2007-03-28 Sciclone Pharmaceuticals Inc Composiciones a base de compuestos inmunoreguladores para el tratamiento o prevencion de infecciones virales respiratorias.
AU2005299609A1 (en) 2004-10-27 2006-05-04 Sciclone Pharmaceuticals, Inc. Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds
WO2006076169A2 (en) 2004-12-28 2006-07-20 Sciclone Pharmaceuticals, Inc. Treatment or prevention of genital viral infections with immunomodulator compounds
US20090074815A1 (en) 2005-04-22 2009-03-19 Sciclone Pharmaceuticals, Inc. Immunomodulator Compounds as Vaccine Enhancers
CA2649575A1 (en) 2006-04-20 2007-11-01 Sciclone Pharmaceuticals, Inc. Treatment of melanoma
KR20090094145A (ko) 2006-12-18 2009-09-03 아칠리온 파르마세우티칼스 인코포레이티드 C형 간염 감염을 치료하기 위한 병용 요법
MX2009008641A (es) * 2007-02-13 2009-09-14 Sciclone Pharmaceuticals Inc Composiciones para el tratamiento o prevencion del deterioro, lesion o daño a tejido debido a enfermedad de las mucosas.
RU2007118237A (ru) 2007-05-17 2008-11-27 ООО "Научно-производственна фирма Верта" (RU) Способ лечения аллергических заболеваний
UA98508C2 (ru) 2007-08-23 2012-05-25 Сайклон Фармасьютикалз, Инк. Иммуномодуляторное производное дипептида для лечения рака легких
JP2011530519A (ja) 2008-08-06 2011-12-22 サイクローン・ファーマシューティカルズ・インコーポレイテッド 免疫調節化合物を用いたc型肝炎の治療または予防の方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109528202A (zh) * 2018-11-14 2019-03-29 北京大学第医院 一种头颈部放疗诊疗系统
CN109528202B (zh) * 2018-11-14 2021-07-16 北京大学第一医院 一种头颈部放疗诊疗系统

Also Published As

Publication number Publication date
IL200364A0 (en) 2010-04-29
AU2008216799A1 (en) 2008-08-21
MX2009008641A (es) 2009-09-14
WO2008100458A3 (en) 2008-11-27
JP2010518160A (ja) 2010-05-27
EP2120986A2 (en) 2009-11-25
US20100086622A1 (en) 2010-04-08
AR065338A1 (es) 2009-06-03
NZ579570A (en) 2012-02-24
WO2008100458A2 (en) 2008-08-21
US7906486B2 (en) 2011-03-15
US20110117211A1 (en) 2011-05-19
UA96980C2 (ru) 2011-12-26
KR20090119897A (ko) 2009-11-20
TW200845958A (en) 2008-12-01
EP2120986A4 (en) 2010-04-07
CA2677749A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
JP2016517434A5 (cg-RX-API-DMAC7.html)
US11123357B2 (en) Methods and compositions for treating oral mucositis
US20240180939A1 (en) Immunomodulatory oligosaccharides for the enhancement of anti-tumor efficacy of immuno-oncology agents
AU2008259864B2 (en) Methods and compositions for administration of Oxybutynin
US7906486B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa
CN1155245A (zh) 胞壁酰肽化合物的应用
CA2516458C (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
CA2386583A1 (en) Novel combination for the treatment of sexual dysfunction
ES2206762T3 (es) Nueva aplicacion terapeutica de un derivado de la tienilciclohexilamina.
CN101448514A (zh) 黑素瘤的治疗
US20240277663A1 (en) Pharmaceutical kits and uses thereof for treating colorectal cancer
EP3827821B1 (en) Use of pharmaceutical composition to treat epilepsy seizure and/or to treat epilepsy associated motor symptom and cognitive impairment
US20110189305A1 (en) Treatment of lung cancer
KR20210039413A (ko) 암의 치료를 위한 병용 요법
US20260083726A1 (en) Compositions, systems, and methods for treating cancer using tumor treating fields, chemotherapeutic agents, and anti-fibrotic agents
CN110141567B (zh) 黄连素在制备治疗放射性口炎药物中的应用
JP2024511019A (ja) メラノサイト増殖促進剤および生存促進因子としての特異的炎症収束性メディエーター(spm)およびその使用
CN119698284A (zh) 用于治疗X-ALD的甲状腺β激动剂给药方案
CN116850187A (zh) Hapalindole在制备抑制肝癌或乳腺癌的药物中的应用
WO2012147834A1 (ja) 放射線増感剤
PeaceHealth et al. N-Acetyl Cysteine
JP2005263762A (ja) 神経因性疼痛に対し鎮痛効果を示す新規組成物
CN1108528A (zh) 生物活性皮肤疗法
JP2014185098A (ja) 造血又は腸管放射線障害防護剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100224